BioCentury
ARTICLE | Strategy

More freedom to deal

March 2, 2009 8:00 AM UTC

With nondilutive cash at a premium, Xencor Inc. is ramping up a partnering campaign built on data that allows the company to expand its XmAb technology into a broader swath of disease areas. The company reached a deal with CSL Ltd. last week, expects to announce a deal with Pfizer Inc. this week, and aims to disclose another soon.

Before last year, according to President and CEO Bassil Dahiyat, the primary focus of Xencor's XmAb antibody optimization technology was the enhanced antibody-dependent cellular cytotoxicity (ADCC) provided by its engineered Fc domains...